JNNP: Cannabinoids in Multiple Sclerosis (CAMS) Study
Cannabinoids in Multiple Sclerosis (CAMS) Study: Safety and Efficacy Data for 12 Months Follow Up
Journal of Neurology, Neurosurgery, & Psychiatry:
Effectiveness and long-term safety of cannabinoids in MS: 630 subjects with stable MS and muscle spasticity, from 33 UK centers, were randomly assigned to receive oral THC (tetrohydrocannabinol, an active ingredient in marijuana), cannabis extract or placebo over 15 weeks. Oral derivatives of marijuana did not provide objective improvement in spasticity (as measured by a standardized assessment tool). However, significantly more participants in the treatment group reported subjective improvements in spasticity and pain (but not in tremor or bladder symptoms). In other words, participants reported feeling improvements that could not be confirmed by the study physicians.
Source: Journal of Neurology, Neurosurgery, & Psychiatry
Zajicek et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76:1664-1669 doi:10.1136/jnnp.2005.070136